Gene Expression in Patients With Advanced or Metastatic Colorectal Cancer Receiving Bevacizumab

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00897754
Recruitment Status : Completed
First Posted : May 12, 2009
Last Update Posted : May 19, 2017
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Eastern Cooperative Oncology Group ( ECOG-ACRIN Cancer Research Group )

Brief Summary:

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors understand how patients respond to treatment.

PURPOSE: This laboratory study is looking at gene expression in patients with advanced or metastatic colorectal cancer receiving bevacizumab.

Condition or disease Intervention/treatment
Colorectal Cancer Genetic: gene expression analysis Genetic: protein expression analysis Genetic: reverse transcriptase-polymerase chain reaction Other: immunoenzyme technique Other: immunohistochemistry staining method Other: immunologic technique

Detailed Description:


  • Determine whether the balance of splice form expression alters susceptibility of tumors in vivo to respond to anti-VEGF therapy.

OUTLINE: Tumor tissue samples collected on clinical trial E-3200 are analyzed for laboratory endpoints.

Study Type : Observational
Actual Enrollment : 200 participants
Observational Model: Other
Time Perspective: Retrospective
Official Title: Alternative Splice Forms of VEGF in Colorectal Cancer - Possible Value in Anti-VEGF Therapy
Actual Study Start Date : July 24, 2007
Actual Primary Completion Date : February 1, 2009
Actual Study Completion Date : February 1, 2009

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Mean scores for VEGFb and pan-VEGF gene expression by IHC [ Time Frame: 1 month ]
  2. Gene expression as measured by tissue microarrays [ Time Frame: 1 month ]
  3. Splice form expression as measured by reverse transcriptase-PCR [ Time Frame: 1 month ]
  4. VEGF165b protein expression as measured by ELISA [ Time Frame: 1 month ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 120 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Samples submitted for research from patients participating in E3200


  • Tumor tissue samples available from patients with advanced or metastatic adenocarcinoma of the colon or rectum

    • Receiving bevacizumab on clinical trial E-3200


  • Not specified


  • See Disease Characteristics

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00897754

Sponsors and Collaborators
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)
Study Chair: David Bates, PhD Bristol Heart Institute at University of Bristol

Responsible Party: ECOG-ACRIN Cancer Research Group Identifier: NCT00897754     History of Changes
Other Study ID Numbers: CDR0000560986
First Posted: May 12, 2009    Key Record Dates
Last Update Posted: May 19, 2017
Last Verified: May 2017

Keywords provided by Eastern Cooperative Oncology Group ( ECOG-ACRIN Cancer Research Group ):
adenocarcinoma of the colon
adenocarcinoma of the rectum
recurrent rectal cancer
stage III rectal cancer
stage IV rectal cancer
recurrent colon cancer
stage III colon cancer
stage IV colon cancer

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases